Description
Adipotide (also known as FTPP or Prohibitin-Targeting Peptide 1) is an experimental research peptide designed to target and reduce white adipose tissue through a novel apoptotic mechanism. Unlike traditional fat-loss pathways that focus on appetite suppression or metabolic stimulation, Adipotide works by selectively binding to the blood vessels that supply fat cells, effectively restricting their nutrient delivery and promoting their elimination.
Mechanism of Action
Adipotide functions by targeting prohibitin proteins present in the vasculature of white adipose tissue. Once bound, it induces apoptosis (programmed cell death) in these blood vessels, reducing blood supply to fat cells. This leads to a measurable decrease in fat mass through natural clearance mechanisms without directly altering metabolic rate.
Research Applications
-
Obesity research: Evaluation of adipose tissue reduction strategies.
-
Metabolic health studies: Investigation into fat-related insulin resistance and associated markers.
-
Novel peptide therapies: Understanding alternative mechanisms beyond appetite suppression.
Key Benefits (For Research Use Only)
-
Targets fat tissue directly without central nervous system interaction.
-
Demonstrates a unique mechanism of adipose reduction via vascular targeting.
-
Potential applications in obesity, diabetes, and metabolic syndrome research.
Specifications
-
Form: Lyophilized peptide powder
-
Molecular Formula: C75H110N22O15
-
Unit Size: 5mg vial
-
Purity: ≥98% (HPLC verified)
-
Storage: Store dry powder at 2–8°C. After reconstitution, store at 2–8°C and use within 30 days.
